Sales Product Lead: To facilitate the rapid adoption and growth of Thyroid GuidePx®, Qualisure is currently seeking a Sales Product Lead to facilitate sales in the US market. This position demands strong collaborative and communication skills, including the ability to…
Read the research behind our Thyroid GuidePx(R) test! A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer SUMMARY Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on prognostication based on…
Listen to our CEO, Dr. Oliver Bathe talk about Qualisure's innovation and the work he's done to transition from being a medical practitioner to a full-time entrepreneur. https://www.buzzsprout.com/766547/12261737
October 19-23 2022. Dr. Oliver Bathe presented results from a study of 742 patients at the 2022 Annual Meeting of the American Thyroid Association. The study demonstrated that Thyroid GuidePx® has a 97% specificity in identifying patients with low-risk papillary…
CALGARY, ALBERTA, Recently Jon Hagan, Senior Business Partner in Marketing and Communications at Alberta Innovates, sat down with our CEO Dr. Oliver Bathe. Jon explored the Qualisure commercialization journey with Dr. Bathe and how Qualisure benefited from accessing Alberta Innovates’…
Qualisure Diagnostics is pleased to announce the launch of our first diagnostic test, Thyroid GuidePx® for papillary thyroid cancer, the most common type of thyroid cancer. Thyroid GuidePx® is the first genomic classifier available for papillary thyroid cancer. This test…
Dr. Steven Craig of the University of Wollongong presented data on the molecular subgroups identified by Thyroid GuidePx™ at the 90th Annual Meeting of the American Thyroid Association. The presentation at the virtual meeting, entitled “Molecular Subgroups Identified by Machine…
Dr. Cynthia Stretch (Chief Scientific Officer) presented details on the molecular features of molecular subgroups of papillary thyroid cancer that are identifiable using Thyroid GuidePx™ at the Annual Meeting of the Canadian Association of Surgical Oncologists (CSSO). In her presentation…
Qualisure has submitted an international PCT patent application for the molecular subclassification of papillary thyroid cancer which is ending review. The Patent Cooperation treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible…
Qualisure was awarded a $100,000 voucher from Alberta Innovates to support further development of lead product Thyroid GuidePx™. The voucher will be applied to performing final validation tests of the clinical assay in preparation for clinical implementation. Alberta Innovates vouchers…